A profile of Synchron, a startup set to trial inserting brain implants via blood vessels, helping those with limited physical mobility use cursors and devices
- Synchron is part of an emerging crop of companies testing technology in the brain-computer interface industry.
Context & Ripple Effects
This CNBC profile lands mid-way through Synchron's capital arc: after a 2021 $40M Series B led by Khosla Ventures and a late-2022 $75M round backed by ARCH Venture, Bezos Expeditions, and Gates Frontier, the company was still in early human testing when the piece ran. Its differentiator is delivery — a stent-like implant threaded through blood vessels rather than open-brain surgery.
The coverage since has validated both bets on the company: an Apple partnership to explore iPhone control via brain signals and, by late 2025, a $200M Series D at a nearly $1B valuation. Against that backdrop, the vascular approach looks less like a niche technique and more like the reason Synchron became the consumer-platform partner of choice.
First-order effects
- People with limited mobility gain cursor and device control through an implant that skips invasive brain surgery — lowering the barrier to enrollment versus craniotomy-based rivals like Neuralink.
- Synchron's trial positions it as the testable alternative in a field where implant recipients are set to double within a year, giving clinicians a less surgically demanding option to offer patients.
Second-order effects
- Competitors with open-skull procedures now compete against a delivery method that scales through interventional cardiology-style insertion, pressuring their risk profiles and recruitment funnels.
- Consumer platforms follow the hardware: Apple's Synchron partnership signals that operating-system makers see brain signals as an accessibility input worth building for, pulling BCI out of pure medical-device territory.
Third-order effects
- If vascular delivery keeps proving out, the bottleneck for BCI adoption shifts from surgical capacity to software integration — favoring companies that pair implants with mainstream device ecosystems.
- Capital concentration around a near-$1B leader suggests the industry consolidates into a few well-funded platforms rather than fragmenting across many small clinical startups.
The trend: Brain-computer interfaces are moving from surgical implants toward minimally invasive vascular delivery paired with mainstream consumer platforms, concentrating capital and partnerships around a small set of leaders.